COVID-19: So What’s New?

Katherine Yang, PharmD, MPH, FCSHP is a Health Sciences Clinical Professor of Pharmacy at the UCSF School of Pharmacy and an infectious diseases clinical pharmacist at the UCSF Medical Center in San Francisco, California. Dr. Yang specializes in the pharmacokinetic and pharmacodynamic optimization of antibiotic dosing for the treatment of multi-drug resistant gram-negative infections. Since the start of the pandemic, Dr. Yang has been heavily involved in the management of COVID-19 therapeutics. 

Sarah Parsons, PharmD, BCPPS is a clinical pharmacy specialist in pediatric infectious diseases at the Children’s Hospital of the King’s Daughters focusing in antimicrobial stewardship and COVID-19 management in pediatric patients. Dr. Parsons received her Bachelor of Science focused in microbiology and immunology from Radford University followed by her Doctor of Pharmacy Degree from Virginia Commonwealth School of Pharmacy. She completed a postgraduate year 1 residency at HCA Health system in Richmond, Virginia. 

Monica Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP is a clinical pharmacy specialist in the outpatient infectious diseases and outpatient parenteral antibiotic therapy clinics at Beth Israel Deaconess Medical Center. Dr. Mahoney received her PharmD degree from Massachusetts College of Pharmacy and Health Sciences in Boston, Massachusetts. She completed postgraduate year 1 residency and postgraduate year 2 infectious diseases residency at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, the Society of Infectious Diseases Pharmacists, and the Infectious Diseases Society of America.

Michael Ganio, PharmD, MS, BCPS, FASHP (he/him) is senior director of pharmacy practice and quality at ASHP. Dr. Ganio joined the staff at ASHP in January 2018, after nearly two decades in hospital and health-system pharmacy practice. His responsibilities at ASHP span the practice of pharmacy and include drug shortages, sterile and non-sterile compounding, hazardous drug safety, and other practice-related topics. 

Relevant Financial Relationship Disclosures

The following persons in control of this activity’s content have relevant financial relationships:

• Monica V. Mahoney: BD Bioscience – Consultant, Speaker’s bureau; GSK – Consultant; Cidara – Consultant; Pfizer – Consultant

All other persons in control of content do not have any relevant financial relationships with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. 

Resources

•  COVID-19 Now and Beyond: Where Do We Go From Here?
•  Office Hours Roundtable: Enhancing Care for Special Patient Populations in the Shadow of the COVID-19 Pandemic